Is ZVRA or ZYME more undervalued in 2026?

CirclFi compares Zevra Therapeutics, Inc. (ZVRA) and Zymeworks Inc. (ZYME) using 13 institutional-grade valuation models. ZVRA has a Quality of Company score of 6.8/10 while ZYME scores 7.2/10.

Which is a better buy — ZVRA or ZYME?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ZVRA and ZYME valuations compare?

ZVRA at $11.40 and ZYME at $25.48 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ZVRA vs ZYME Valuation Comparison 2026 — Intrinsic Value Analysis

ZVRA

Biotechnology

Zevra Therapeutics, Inc.

Quality

6.8

out of 10

Value Trap

LOW

Price

$11.40

Last close

Models

12/13

Active

ZYME

Biotechnology

Zymeworks Inc.

Quality

7.2

out of 10

Value Trap

SAFE

Price

$25.48

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	ZVRA Fair Value	ZVRA Upside	ZYME Fair Value	ZYME Upside
Bayesian DCF	Intrinsic	$7.88	-30.9%	$6.77	-73.4%
Earnings Power Value	Intrinsic	$8.07	-29.2%	$13.29	-52.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ZVRA vs ZYME — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ZVRA vs ZYME — Which Stock Is More Undervalued?

ZYME scores higher with a 7.2/10 quality rating vs ZVRA's 6.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Zevra Therapeutics, Inc. (ZVRA) and Zymeworks Inc. (ZYME) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ZVRA currently trades at $11.40 with a QOC of 6.8/10, while ZYME trades at $25.48 with a QOC of 7.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).